Astrana Health (ASTH) Competitors

Amentum (NYSE:AMTM) and Astrana Health (NASDAQ:ASTH) are both business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Is AMTM or ASTH more profitable?

Astrana Health has a net margin of 1.04% compared to Amentum's net margin of 0.41%. Amentum's return on equity of 10.90% beat Astrana Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amentum	0.41%	10.90%	4.18%
Astrana Health	1.04%	3.43%	1.87%

Does the media favor AMTM or ASTH?

In the previous week, Amentum had 4 more articles in the media than Astrana Health. MarketBeat recorded 18 mentions for Amentum and 14 mentions for Astrana Health. Amentum's average media sentiment score of 0.92 beat Astrana Health's score of 0.31 indicating that Amentum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amentum	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrana Health	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do institutionals and insiders have more ownership in AMTM or ASTH?

39.9% of Amentum shares are held by institutional investors. Comparatively, 52.8% of Astrana Health shares are held by institutional investors. 18.7% of Amentum shares are held by insiders. Comparatively, 20.0% of Astrana Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts recommend AMTM or ASTH?

Amentum currently has a consensus price target of $27.00, suggesting a potential upside of 6.14%. Astrana Health has a consensus price target of $53.29, suggesting a potential upside of 80.38%. Given Astrana Health's stronger consensus rating and higher probable upside, analysts plainly believe Astrana Health is more favorable than Amentum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amentum	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Astrana Health	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has preferable earnings and valuation, AMTM or ASTH?

Astrana Health has lower revenue, but higher earnings than Amentum. Astrana Health is trading at a lower price-to-earnings ratio than Amentum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amentum	$8.39B	0.74	-$82M	$0.39	65.22
Astrana Health	$2.03B	0.81	$43.15M	$0.51	57.92

Summary

Astrana Health beats Amentum on 9 of the 15 factors compared between the two stocks.